Belova L A, Mashin V V, Dolgova D R, Kuvayskaya A A, Kruglova L R, Sukhikh S S, Plaksina T D
Ulyanovsk State University, Ulyanovsk, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2023;123(6):63-71. doi: 10.17116/jnevro202312306163.
To evaluate the effectiveness of the Cytoflavin in patients with dyscirculatory encephalopathy (DE) who had a new coronavirus infection.
82 patients were examined: 16 (19.5%) men and 66 (80.5%) women aged 58 to 80 years, mean age 69±6 years and 70±6 years, respectively. All patients had moderate vascular cognitive impairment (less than 26 points according to the MoCA test), a history of COVID-19 in the period from 3 to 12 months before the start of the study. Patients before COVID-19 were registered with a neurologist with chronic cerebrovascular diseases with non-demented cognitive impairment of vascular origin. Patients of the main group (MG) received the Cytoflavin from the 1st to the 25 day of observation, inclusive, 2 tablets 2 times a day against the background of standard basic therapy. Patients in the comparison group received only standard basic therapy.
It was found that during therapy with Cytoflavin, patients noted a positive trend in the form of a decrease in the symptoms of cognitive impairment, improved orientation and working memory, concentration of attention and counting. Also, patients in MG noted a decrease in fatigue and depressive disorders, an increase in motivation and a positive attitude, the emergence of interest in life, an improvement in the emotional background of mood, an increase in physical activity and working capacity. Comparing the mechanisms of development of vascular dysfunction, a pathogenetic commonality between DE and the development of consequences in the form of cognitive impairment caused by COVID-19 was noted.
Cytoflavin therapy at a dosage of 2 tablets 2 times a day for 25 days can be recommended as part of complex therapy for patients with DE and a COVID-19.
评估细胞黄素对患有新型冠状病毒感染的循环障碍性脑病（DE）患者的疗效。
对82例患者进行了检查：16例（19.5%）男性和66例（80.5%）女性，年龄在58至80岁之间，平均年龄分别为69±6岁和70±6岁。所有患者均有中度血管性认知障碍（根据MoCA测试得分低于26分），在研究开始前3至12个月内有新冠病毒病病史。新冠病毒病之前，患者在神经科登记为患有慢性脑血管疾病且有非痴呆性血管源性认知障碍。主要组（MG）患者在观察的第1天至第25天（含）接受细胞黄素治疗，在标准基础治疗的背景下，每天2次，每次2片。对照组患者仅接受标准基础治疗。
发现在使用细胞黄素治疗期间，患者指出认知障碍症状减轻、定向力和工作记忆改善、注意力和计数能力集中等呈积极趋势。此外，MG组患者还指出疲劳和抑郁障碍减轻、动力和积极态度增强、对生活产生兴趣、情绪背景改善、身体活动和工作能力提高。比较血管功能障碍的发展机制时，注意到DE与新冠病毒病所致认知障碍形式的后果发展之间存在发病机制上的共性。
对于患有DE和新冠病毒病的患者，可推荐每天2次，每次2片，服用25天的细胞黄素治疗作为综合治疗的一部分。
